Home Stock

Stock Research: Fulcrum Therapeutics

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Fulcrum Therapeutics

NMQ:FULC US3596161097
91
  • Value
    75
  • Growth
    72
  • Safety
    Safety
    40
  • Combined
    79
  • Sentiment
    75
  • 360° View
    360° View
    91
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecules for genetically defined rare diseases. It operates in the biopharmaceutical industry, focusing on therapies for conditions like sickle cell disease and inherited aplastic anemias (Diamond-Blackfan anemia, Shwachman-Diamond syndrome, and Fanconi anemia). In the last fiscal year, the company had 45 employees, a market cap of $425 million, $0 profits, and $80 million in revenue.

more

ANALYSIS: With an Obermatt 360° View of 91 (better than 91% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Fulcrum Therapeutics are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Fulcrum Therapeutics. The consolidated Value Rank has an attractive rank of 75, which means that the share price of Fulcrum Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 75% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 72, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 75. But the company’s financing is risky with a Safety rank of 40. This means 60% of comparable companies have a safer financing structure than Fulcrum Therapeutics. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Market Pulse
Country USA
Industry Pharmaceuticals
Size Small
Website fulcrumtx.com
Index
NASDAQ
Fulcrum Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
75 63 29 39
Growth
72 19 97 19
Safety
Safety
40 65 79 79
Sentiment
75 10 54 59
360° View
360° View
91 49 17 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
28 1 39 47
Opinions Change
50 50 72 50
Pro Holdings
n/a 25 54 73
Market Pulse
100 32 41 42
Sentiment
75 10 54 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
75 63 29 39
Growth
72 19 97 19
Safety Safety
40 65 79 79
Combined
79 54 82 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
48 54 3 11
Price vs. Earnings (P/E)
66 18 18 18
Price vs. Book (P/B)
69 73 62 54
Dividend Yield
1 1 1 1
Value
75 63 29 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
1 8 81 13
Profit Growth
37 89 60 37
Capital Growth
67 27 99 15
Stock Returns
76 17 61 83
Growth
72 19 97 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
76 100 100 73
Refinancing
38 92 83 81
Liquidity
17 1 6 6
Safety Safety
40 65 79 79

Similar Stocks

Discover high‑ranked alternatives to Fulcrum Therapeutics and broaden your portfolio horizons.

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Corteva

NYQ:CTVA
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews